Tempus AI advances its genomics push with new assays, CDx progress and plans for whole-genome sequencing to drive future growth.

Artificial intelligence (AI) is set to transform the care of women with cancer. From early detection via digital phenotyping ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously ...

Investing.com -- Verastem Inc (NASDAQ:VSTM) stock dropped 7.8% in after-hours trading Thursday following the company’s announcement of a proposed public offering of common stock.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell ...

A deep spatial proteomic analysis of healthy fallopian tube epithelium, matching high-grade serous ovarian cancer (HGSOC) ...

She explained that for patients with certain p53 mutations, combining existing FDA-approved drugs might finally allow hormone ...

Scientists at The Wistar Institute have solved a longstanding puzzle in ovarian cancer treatment: why anti-estrogen therapy ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported ...

This study evaluated the efficacy and safety of avutometinib (rapidly accelerated fibrosarcoma/mitogen-activated extracellular signal-regulated kinase [MEK] clamp ...

Carla Peoples says she'd been “totally healthy” all her life when she noticed subtle changes in her body. There was some bloating that progressed to the point where it caused her belly stick out. “I ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...